Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 |
| clinicaltrials |
| NCT00109005 | Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 20 | Baylor Research InstituteOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT00068666 | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System | terminated | Phase 2 | 41 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT00256230 | Disulfiram in Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 7 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02962947 | MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | unknown | Phase 2 / Phase 3 | 546 | Azienda Sanitaria di FirenzeOTHER | 0 | Nov 15, 2016 | clinicaltrials |
| NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | terminated | Phase 2 | 12 | EMD SeronoINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01251978 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | completed | Phase 2 | 10 | New England Retina AssociatesOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT00135408 | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | completed | Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 28, 2016 | clinicaltrials |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 155 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2016 | clinicaltrials |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions(MRX34-102) | withdrawn | Phase 1 / Phase 2 | 0 | Mirna Therapeutics, Inc.INDUSTRY | 0 | Sep 27, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | terminated | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT01278940 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 31 | Oslo University HospitalOTHER | 0 | Aug 15, 2016 | clinicaltrials |
| NCT01216696 | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1(CTLA4 NY-ESO-1) | completed | Phase 2 | 25 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Aug 12, 2016 | clinicaltrials |
| NCT01248936 | A Study of RO5185426 in Patients With Metastatic Melanoma | completed | Phase 2 | 374 | Hoffmann-La RocheINDUSTRY | 1 | Aug 12, 2016 | clinicaltrials |
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | terminated | Phase 1 / Phase 2 | 18 | Nantes University HospitalOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00724841 | A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Gemin XINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00948480 | Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells(DCVaccineMel) | completed | Phase 2 | 56 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00005610 | Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | completed | Phase 2 | 28 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00098553 | Everolimus in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 53 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT02062359 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02759536 | In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma | unknown | Phase 1 / Phase 2 | 30 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT01316692 | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma | terminated | Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT02061007 | Biomarker Correlates of Hypoxia in Metastatic Melanoma | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | May 9, 2016 | clinicaltrials |
| NCT02285413 | Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients | completed | Phase 2 | 54 | Radboud University Medical CenterOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | AGIRx Ltd.INDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02202200 | Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma(OPTIMUM) | unknown | Phase 1 / Phase 2 | 40 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT00004104 | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | completed | Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01455259 | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Uppsala UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00738361 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | completed | Phase 2 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2017source: clinicaltrials